Gene therapy for rare blood disease shows promise in Long-Term Follow-Up

NCT ID NCT07527975

First seen Apr 19, 2026 · Last updated Apr 29, 2026 · Updated 1 time

Summary

This study checks the long-term safety and effectiveness of a gene therapy called RP-L102 for people with Fanconi Anemia, a rare genetic condition that causes bone marrow failure and raises cancer risk. About 14 patients who already received RP-L102 in earlier studies will be followed for years to see if their blood counts stay stable, if they avoid needing a bone marrow transplant, and if any side effects appear. The goal is to understand whether this one-time treatment can help control the disease over time.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for FANCONI ANEMIA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • Hospital Infantil Universitario Niño Jesús

    Madrid, 28009, Spain

  • Lucille Packard Children's Hospital, Stanford University

    Palo Alto, California, 94305, United States

  • University College London Great Ormond Street Institute of Child Health (GOSH)

    London, WC1N 1EH, United Kingdom

Conditions

Explore the condition pages connected to this study.